Clinical Trial Update: Raltegravir Added to Stable HAART in HIV-1 Infected Subjects With Viral Suppression and Low CD4 Recovery [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating adding raltegravir to stable HAART in HIV-1-infected subjects with viral suppression and low CD4 recovery was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Raltegravir (raltegravir)

Snippet

Sponsor: Pedro Cahn | Conditions: HIV Infections | Phase 3 | Status: TERMINATED